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Abstract
A theory for direct quantitative analysis of an antigen is proposed. It is based on a potential ho-
mogenous immunoreaction system. It establishes an equation to describe the concentration change
of the antigen and antibody complex. A maximum point is found in the concentration profile of the
complex which can be used to calculate the concentration of the antigen. An experimental scheme
was designed for a commercial time-resolved fluoroimmunoassay kit for HBsAg, which is based het-
erogeneous immunoreaction. The results showed that the theory is practically applicable.
1 Introduction
Antigen is a substance that was introduced into the body of a living organism, which will lead to a disease
sometimes. The invading of antigen will trigger the generation of an substance called antibody by the
immune system of the organism. The antibody plays the role to kill or neutralize the antigen. This kind
of reaction between antigen and antibody have found application in qualitative analysis and quantitative
analysis of antigen. The main topic of this paper focuses on the quantitative analysis.
A well known method to detect an antigen is the enzyme-linked immunosorbent assay (ELISA)[1, 2,
3]. It mostly focuses on detecting the presence of an antigen. With the increasing demand on quantitative
analysis of antigen in the diagnosis and treatment of a diesease such as hepatitis B, the time-resolved
fluoroimmunoassay (TRFIA) gradually shows its advantages[4, 5, 6] . The TRFIA makes the best use of
fluorescence delay effect of europium (Eu) to eliminates the background fluorescence[7]. So, the TRFIA
is especially adapted in complicated sample such as sera.
There is a problem with the existing quantitative methods for antigens. They usually need the stan-
dard substance of the antigen in the calibration procedure of a measurement[8]. This procedure has
been an indispensable part of presently existing quantitative analysis based on analytical instruments.
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However, the expense on the standard substance is a huge burden when the substance is expensive.
Furthermore, when the standard substance is not available, the quantitative analysis can not be imple-
mented.
The purpose of this paper is to establish a general theory of quantitative analysis that does not rely on
the standard substance of target antigen. The theory was developed based on a potential homogenous
immunoreaction system. It was finally applied to the direct quantitative analysis of HBsAg by designing
an experimental scheme for heterogeneous immunoreaction.
2 Theory
Figure 1 shows the fundamental principal and experimental steps of a commerical time-resolved flu-
oroimmunoassy (TRFIA) kit for HBsAg. The double antibodies sandwich technology ensures that one
antigen (Ag) combines with one labeled antibody (Abx) [9]. This kind of reaction mode is the require-
ment for quantiative analysis of the Ag. Thus, the reaction between Ag and Abx can be expressed as
follows:
Ag+Abx → Ag ·Abx (1)
where x represents a label such as Eu3+. Final measurement is usually based on the label. We assume
the initial concentrations of Ag and Abx are CAg and CAbx, respectively. When Vt volume of Abx’s solution
is added into V0 volume of Ag’s solution, the mass balances are as following
CAgVt
V0 + Vt
= [CAg] + [Ag ·Abx] (2)
CAbxVt
V0 + Vt
= [CAbx] + [Ag ·Abx] (3)
where [ ] represents the equilibrium concentration of the corresponding species. From equation (2) and
equation (3), we get
[Ag ·Abx] =
g(ρ)−
p
g2(ρ)− h(ρ)
2
(4)
where ρ =
Vt
V0
;g(ρ) =
ρCAbx+CAg
1+ρ
+ 1
K
; h(ρ) =
4ρCAgCAbx
(1+ρ)2
; K =
[CAg·Abx]
[CAg][CAbx]
.
There is a maximum point in the plot of [Ag ·Abx] versus ρ according to equation (4). The first
derivation of [Ag ·Abx] versus ρ is
[Ag ·Abx]′ =
g′(ρ)
2
−
1
4
[g2(ρ)− h(ρ)]−
1
2 [2g(ρ)g′(ρ)− h′(ρ)] (5)
where g′(ρ) =
CAbx−CAg
(1+ρ)2
; h′(ρ) =
4CAgCAbx(1−ρ)
(ρ+1)3
.
Let [Ag ·Abx]′ = 0, we finally get
ρ
0
=
CAgCAbx±
q
CAg + CAbx+
1
K
 (CAg−CAbx)2
K
C2
Abx
+
CAbx−CAg
K
(6)
where ρ
0
is the ρ value at the maximum point.
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And it can be proved that the ρ
0
at the maximum point will be
lim
K→∞
ρ
0
=
CAg
CAbx
. (7)
Equation (7) shows that the concentration of the Ag can be calculated without using calibration
procedure. The requisite condition is that the generated antigen antibody complex, the Ag ·Abx, is stable
enough. The relative error of the estimation is
r.e. =
ρ
0
−
CAg
CAbx
CAg
CAbx
=
C2
Abx
±
CAbx
CAg
q
CAg+ CAbx+
1
K
 (CAg−CAbx)2
K
C2
Abx
+
CAbx−CAg
K
− 1. (8)
Obviously, lim
K→∞
r.e. = 0. Similar results can be obtained when CAg = CAbx.
Above theory is actually based on homogeneous system. The final measurement is based on labeled
antiboy. It needs quite an effort to apply the theory to practical system because of the lack of proper
reagent kit. This situation could be changed in near future by using the homogeneous fluroimmunoassay
(HFIA)[9]. However, a properly designed experimental scheme can apply the theory in another way.
3 An application to TRFIA of HBsAg
Figure 1 shows a standard scheme for quantitative analysis of HBsAg using TRFIA. In the first incubation,
the added HBsAg is fixed by the solid phase anti-HBs in the well. So, in the second incubation, the
introduced Eu-labeled anti-HBs will combine with the HBsAg in 1:1 ratio. The measured fluorescence
intensity of Eu in final step will be directly propotional to the quantity of the HBsAg.
Figure 1: The basic steps of a commercial TRFIA kit for HBsAg.
We designed an experimental scheme and shown it in Table 1. In the scheme, the quantities of HBsAg
in the wells are fixed which limits the binding quantity of the Eu-labelled anti-HBs in each of the wells.
For the convenience of discussion, we assume the HBsAg quantity in each well is CHBsAgV0 mol. When
Canti−HBs−EuVt > CHBsAgV0, extra added Eu-labelled anti-HBs will be washed out. On the other hand,
when Canti−HBs−EuVt < CHBsAgV0, the added Eu-labelled anti-HBs is totally combined with the HBsAg.
The equations (2) and (3) hold under the latter situation.
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Table 1: An experimental scheme for direct quantitative analysis of HBsAg
Wells 1 2 3 4 5 6 7 8
V0 (µL)
a 100 100 100 100 100 100 100 100
Vt (µL)
b 20 40 60 80 100 120 140 160
(V0 + Vt) (µL)
c 120 140 160 180 200 220 240 260
a Volume of HBsAg.
b Volume of anti-HBs-Eu.
c Volume of enhancement solution.
The more important thing is that the final measurement is based on the quantity of Eu released by
enhancement solution rather than antigen or antibody or antigen antibody complex. So, if we put the
Eu in a volume variation environment like equations (2) and (3), equation (4) can be used to describe
its concentration change. Finally, equation (7) can be used to calculate the concentration of HBsAg. The
third line in Table 1 simulates equation (3) by adding Eu-labelled anti-HBs into the wells progressively.
The most important operation is listed in the last line of Table 1, which offers the final Eu a circumstance
of volume variation. So, Eu has same concentration change as the antigen and antibody complex as
shown in equation (4).
4 Experiments
The TRFIA kit for HBsAg were from Guangzhou Darui Antibody Engineering And Technology Co. Ltd..
The sera for quality control were taken as unknown samples. The instrument was the Victor X5 Multilabel
Plate Reader of PerkinElmer. TopPette Pipettors (Dragon Medical (Shanghai) Ltd.) were used to add
solutions. The volumes of the reagents are shown in Table 1. Experimental operations were done in
accordance with the kit’s manual. Five repeat measurements were implemented.
5 Results
Figure 2 shows the fluorescence intensities of Eu versus volume ratio. The solid line is the curve fitting
result of the mean intensities using equation (4). The maximum point in the curve is used to calculate the
concentration of the HBsAg. Table 2 shows the calculated results of two sera. It must note that fluores-
cence intensity should be adjust to unit volume because the instrument only recordes total fluorescence
intensity.
6 Conclusion
We successfully established a general theory for the direct quantitative analysis of antigen. The theory
is self-contained mathematically. The application examples also show practicability of the theory. The
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Figure 2: An example of fluorescence intensity of Eu with ρ.
Table 2: Measurement results of HBsAg (Canti−HBs−Eu = 0.00627µmol/L)
Real concentration
of HBsAg
Mean ρ value at max
point, variance and re-
peat number
Calculated con-
centration of
HBsAg
Relative
error
0.00417 µmol/L 0.760, 0.035, 5 0.00477 µmol/L 14.3%
0.00625 µmol/L 0.813, 0.0050, 5 0.00510 µmol/L -18.5%
advantage of the theory can be shown when the standard substances are extremely expensive or there are
even no standard substances available. More experiments are still needed to make it a routine mehtod.
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